Firefly Neuroscience

What exists: 1) Intangible assets. Firefly holds an FDA 510(k) predicate for BNA software (2014) and sells an FDA‑cleared Evoke EEG System (2017), now in the FDA GUDID as commercially distributed. The company reports 23 issued U.S. patents with expirations from 2028 to 2037 and emphasizes a growing proprietary EEG/ERP dataset.

These create some IP and data differentiation but not exclusivity. 2) Switching costs. Subscription hardware with training and workflow integration adds friction, yet neurologists and behavioral health clinics can substitute with other EEG/qEEG vendors, limiting stickiness. 3) Network effects.

More scans may improve algorithms, but this is a data‑scale effect rather than a classic multi‑sided network; benefit accrues slowly and is not unique to Firefly. 4) Cost advantages. None evident versus established EEG hardware and software providers. 5) Efficient scale.

The niche is fragmented with multiple FDA‑cleared alternatives (for example VoxNeuro, BrainView, NeuroField), so efficient‑scale dynamics are weak. Component scores: Intangibles 45, Switching costs 30, Network effects 25, Cost advantages 20, Efficient scale 25; weighted to 31 overall.